A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Key facts

Sponsor

Cybrexa Therapeutics

Principal Investigator

Michael Needle, MD, MD

Cybrexa Therapeutics

Intervention

CBX-12(drug)

Enrollment

40 enrolled

Eligibility

18 years · FEMALE

Timeline

2024 – 2025

Study locations (17)

• Honor Health, Scottsdale, Arizona, United States
• Arizona Oncology Associates, Tucson, Arizona, United States
• Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
• Yale University School of Medicine, New Haven, Connecticut, United States
• D&H Cancer Research Center, Margate, Florida, United States
• South Florida Gynecology, Tampa, Florida, United States
• Northwest Cancer Centers, Dyer, Indiana, United States
• Norton Cancer Institute, Louisville, Kentucky, United States
• Women's Cancer Care, Covington, Louisiana, United States
• Pci Nyu Langone Health, New York, New York, United States
• Albert Einstein College of Medicine Montefiore Medical, New York, New York, United States
• University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
• Oncology Associates of Oregon, Eugene, Oregon, United States
• Allegheny Singer Research Institute D/B/A Ahn Research Institution, Pittsburgh, Pennsylvania, United States
• Mary Crowley Cancer Research, Dallas, Texas, United States
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07508306
  Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity
  Faculty of Medicine of Tunis
• RECRUITINGPHASE1NCT07524322
  Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  Regor Pharmaceuticals Inc.
• RECRUITINGPHASE1NCT06366490
  Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
  PhotonPharma, Inc.
• RECRUITINGPHASE1NCT07402915
  Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
  AstraZeneca
• RECRUITINGPHASE2NCT07158021
  Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
  University of Michigan Rogel Cancer Center
• RECRUITINGNANCT07280312
  Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
  Mayo Clinic
• RECRUITINGPHASE2NCT06971744
  Autophagy Maintenance (AUTOMAIN)
  Medical University of South Carolina
• RECRUITINGPHASE3NCT07544030
  A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
  tongweihua

See all trials for Malignant epithelial tumor of ovary →